Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenfluramine in infants with Dravet syndrome
2022-502359-75-00Phase 3Completed
- Sponsor
- UCB
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of fenfluramine in Dravet syndrome, sponsored by UCB. Primary endpoints: Change from baseline in QTcF at end of treatment, Drug-associated valvulopathy occurrence and 4 more. Started Jul 2024; status: completed.
02
Drugs
fenfluramine
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on 2022-502359-75-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502359-75-00.